918967-40-5

Basic information

• Product Name: Benzenesulfonamide, 4-cyano-2-fluoro-
• Synonyms: 4-cyano-2-fluorobenzenesulphonamide;Benzenesulfonamide,4-cyano-2-fluoro;4-cyano-2-fluorobenzene-1-sulfonamide
• CAS NO: 918967-40-5
• Molecular Formula: C7H5FN2O2S
• Molecular Weight: 200.193
• Mol File: 918967-40-5.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 392.8±52.0 °C(Predicted)
• Density: 1.55±0.1 g/cm3(Predicted)
• CAS DataBase Reference: Benzenesulfonamide, 4-cyano-2-fluoro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenesulfonamide, 4-cyano-2-fluoro-(918967-40-5)
• EPA Substance Registry System: Benzenesulfonamide, 4-cyano-2-fluoro-(918967-40-5)

Safety Data

• Hazardous Substances Data: 918967-40-5(Hazardous Substances Data)

Upstream product

• 64248-62-0 3,4-Difluorobenzonitrile 
• 133059-44-6 4-bromo-3-fluorobenzonitrile 
• 63069-50-1 4-cyano-2-fluoroaniline 
• 918967-78-9 4-cyano-2-fluorobenzene-1-sulfonyl chloride 

Downstream Products

• 918967-58-5 3-fluoro-N-hydroxy-4-sulfamoylbenzamidine 

Relevant articles and documents

Synergistic Experimental and Computational Investigation of the Bioorthogonal Reactivity of Substituted Aryltetrazines

Tetrazines (Tz) have been applied as bioorthogonal agents for various biomedical applications, including pretargeted imaging approaches. In radioimmunoimaging, pretargeting increases the target-to-background ratio while simultaneously reducing the radiation burden. We have recently reported a strategy to directly 18F-label highly reactive tetrazines based on a 3-(3-fluorophenyl)-Tz core structure. Herein, we report a kinetic study on this versatile scaffold. A library of 40 different tetrazines was prepared, fully characterized, and investigated with an emphasis on second-order rate constants for the reaction with trans-cyclooctene (TCO). Our results reveal the effects of various substitution patterns and moreover demonstrate the importance of measuring reactivities in the solvent of interest, as click rates in different solvents do not necessarily correlate well. In particular, we report that tetrazines modified in the 2-position of the phenyl substituent show high intrinsic reactivity toward TCO, which is diminished in aqueous systems by unfavorable solvent effects. The obtained results enable the prediction of the bioorthogonal reactivity and thereby facilitate the development of the next generation of substituted aryltetrazines for in vivo applications.

HETEROCYCLIC COMPOUNDS WITH AN ROR(GAMMA)T MODULATING ACTIVITY

The present invention relates to a compound that may have an ROR(gamma)t modulating activity and can thus be useful in the treatment of cancer.

HETEROCYCLIC GPCR AGONISTS

Compounds of formula (I) or pharmaceutically acceptable salts thereof, are agonists of GPR119 and are useful as regulators of satiety, e.g. for the treatment of obesity, and for the treatment of diabetes.